» Articles » PMID: 38393111

Development of Virus-like Particle Plant-Based Vaccines Against Avian H5 and H9 Influenza A Viruses

Overview
Journal Vet Sci
Publisher MDPI
Date 2024 Feb 23
PMID 38393111
Authors
Affiliations
Soon will be listed here.
Abstract

Avian influenza A virus (AIV) is a significant cause of mortality in poultry, causing substantial economic loss, particularly in developing countries, and has zoonotic potential. For example, highly pathogenic avian influenza (HPAI) viruses of the H5 subtype have been circulating in Egypt for around two decades. In the last decade, H5N1 viruses of clade 2.2.1 have been succeeded by the antigenically distinct H5N8 clade 2.3.4.4b viruses. Furthermore, H9N2 viruses co-circulate with the H5N8 viruses in Egyptian poultry. It is widely recognised that effective vaccination against IAV requires a close antigenic match between the vaccine and viruses circulating in the field. Therefore, approaches to develop cost-effective vaccines that can be rapidly adapted to local virus strains are required for developing countries such as Egypt. In this project, the haemagglutinin (HA) proteins of Egyptian H5 and H9 viruses were expressed by transient transfection of plants (). The formation of virus-like particles (VLPs) was confirmed by transmission electron microscopy. Mice were immunised with four doses of either H5 or H9 VLPs with adjuvant. Antibody and cellular immune responses were measured against the corresponding recombinant protein using ELISA and enzyme-linked immunosorbent assay (ELISpot), respectively. Chickens were immunised with one dose of H5 VLPs, eliciting HA-specific antibodies measured by ELISA and a pseudotyped virus neutralisation test using a heterologous H5 HA. In conclusion, plant-based VLP vaccines have potential for producing an effective vaccine candidate within a short time at a relatively low cost.

Citing Articles

Virus-like particles in poultry disease: an approach to effective and safe vaccination.

Raji A, Dastjerdi P, Omar A Front Vet Sci. 2024; 11:1405605.

PMID: 39315089 PMC: 11417104. DOI: 10.3389/fvets.2024.1405605.

References
1.
Kandeil A, Kayed A, Moatasim Y, Webby R, McKenzie P, Kayali G . Genetic characterization of highly pathogenic avian influenza A H5N8 viruses isolated from wild birds in Egypt. J Gen Virol. 2017; 98(7):1573-1586. PMC: 5817258. DOI: 10.1099/jgv.0.000847. View

2.
Pusch E, Suarez D . The Multifaceted Zoonotic Risk of H9N2 Avian Influenza. Vet Sci. 2018; 5(4). PMC: 6313933. DOI: 10.3390/vetsci5040082. View

3.
Stephenson I, Nicholson K, Gluck R, Mischler R, Newman R, Palache A . Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet. 2003; 362(9400):1959-66. DOI: 10.1016/S0140-6736(03)15014-3. View

4.
Mortimer E, Maclean J, Mbewana S, Buys A, Williamson A, Hitzeroth I . Setting up a platform for plant-based influenza virus vaccine production in South Africa. BMC Biotechnol. 2012; 12:14. PMC: 3358240. DOI: 10.1186/1472-6750-12-14. View

5.
Ward B, Makarkov A, Seguin A, Pillet S, Trepanier S, Dhaliwall J . Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials. Lancet. 2020; 396(10261):1491-1503. DOI: 10.1016/S0140-6736(20)32014-6. View